Phase I trial of intramuscular injection of a recombinant adeno-associated virus serotype 2 alphal-antitrypsin (AAT) vector in AAT-deficient adults.
暂无分享,去创建一个
Sihong Song | Terence R Flotte | T. Conlon | T. Flotte | B. Byrne | N. Muzyczka | A. Poirier | K. Berns | Sihong Song | M. Brantly | Mark L Brantly | L Terry Spencer | Barry J Byrne | Carolyn T Spencer | Margaret Humphries | Richard O Snyder | D. Baker | Nicholas Muzyczka | Thomas J Conlon | Amy Poirier | Wendy Garlington | Dawn Baker | Kenneth I Berns | W. Garlington | R. Snyder | C. Spencer | M. Humphries | L. Spencer
[1] B. Byrne,et al. CMV-beta-actin promoter directs higher expression from an adeno-associated viral vector in the liver than the cytomegalovirus or elongation factor 1 alpha promoter and results in therapeutic levels of human factor X in mice. , 2001, Human gene therapy.
[2] T. Flotte,et al. Therapeutic level of functional human alpha 1 antitrypsin (hAAT) secreted from murine muscle transduced by adeno‐associated virus (rAAV1) vector , 2006, The journal of gene medicine.
[3] T. Flotte,et al. Effect Of DNA-dependent protein kinase on the molecular fate of the rAAV2 genome in skeletal muscle , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[4] R. Crystal. The α1-antitrypsin gene and its deficiency states , 1989 .
[5] R. Crystal,et al. Biochemical Efficacy and Safety of Monthly Augmentation Therapy for α1-Antitrypsin Deficiency , 1988 .
[6] James M. Wilson,et al. Gene Therapy Vectors Based on Adeno-Associated Virus Type 1 , 1999, Journal of Virology.
[7] R. Stockley,et al. Alpha-1-antitrypsin replacement therapy: current status , 2006, Current opinion in pulmonary medicine.
[8] T. Flotte,et al. Adeno-associated virus: a ubiquitous commensal of mammals. , 2005, Human gene therapy.
[9] R. Crystal,et al. Experience with replacement therapy in the destructive lung disease associated with severe alpha-1-antitrypsin deficiency. , 1983, The American review of respiratory disease.
[10] T. Conlon,et al. Enhancing rAAV vector expression in the lung , 2005, The journal of gene medicine.
[11] Lili Wang,et al. Gene transfer into skeletal muscle using novel AAV serotypes , 2005, The journal of gene medicine.
[12] M. Zern,et al. A novel SV40-based vector successfully transduces and expresses an alpha 1-antitrypsin ribozyme in a human hepatoma-derived cell line , 1999, Gene Therapy.
[13] James M. Wilson,et al. Recombinant adeno-associated virus for muscle directed gene therapy , 1997, Nature Medicine.
[14] John E. Murphy,et al. Adeno-associated virus-mediated delivery of erythropoietin leads to sustained elevation of hematocrit in nonhuman primates , 1998, Gene Therapy.
[15] James M. Wilson,et al. Stable gene transfer and expression of human blood coagulation factor IX after intramuscular injection of recombinant adeno-associated virus. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[16] P. Laipis,et al. Stable therapeutic serum levels of human alpha-1 antitrypsin (AAT) after portal vein injection of recombinant adeno-associated virus (rAAV) vectors , 2001, Gene Therapy.
[17] B. Meyrick,et al. Transfection of nasal mucosa with a normal alpha1-antitrypsin gene in alpha1-antitrypsin-deficient subjects: comparison with protein therapy. , 2000, Human gene therapy.
[18] R. Snyder,et al. Production of research and clinical‐grade recombinant adeno‐associated virus vectors , 2005 .
[19] J. Escobedo,et al. Transient immunosuppression allows transgene expression following readministration of adeno-associated viral vectors. , 1998, Human gene therapy.
[20] T. Flotte. Adeno-associated virus-mediated gene transfer for lung diseases. , 2005, Human gene therapy.
[21] Alan McClelland,et al. AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. , 2003, Blood.
[22] E. Work,et al. Laboratory techniques in biochemistry and molecular biology , 1969 .
[23] M. Kay,et al. Efficient lentiviral transduction of liver requires cell cycling in vivo , 2000, Nature Genetics.
[24] T. Flotte,et al. A novel antiapoptotic role for alpha1-antitrypsin in the prevention of pulmonary emphysema. , 2006, American journal of respiratory and critical care medicine.
[25] D. Grimm,et al. Novel tools for production and purification of recombinant adenoassociated virus vectors. , 1998, Human gene therapy.
[26] A. Heguy,et al. Intrapleural 'outside-in' gene therapy: therapeutics for organs of the chest via gene transfer to the pleura. , 2005, Current opinion in molecular therapeutics.
[27] T. Flotte. Recent developments in recombinant AAV-mediated gene therapy for lung diseases. , 2005, Current gene therapy.
[28] T. Flotte,et al. Intramuscular administration of recombinant adeno-associated virus 2 alpha-1 antitrypsin (rAAV-SERPINA1) vectors in a nonhuman primate model: safety and immunologic aspects. , 2002, Molecular therapy : the journal of the American Society of Gene Therapy.
[29] Alan McClelland,et al. Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector , 2000, Nature Genetics.
[30] R. Crystal,et al. Replacement therapy for alpha 1-antitrypsin deficiency associated with emphysema. , 1987, The New England journal of medicine.
[31] R. Herzog,et al. Systemic protein delivery by muscle-gene transfer is limited by a local immune response. , 2005, Blood.
[32] I. Bossis,et al. Reengineered salivary glands are stable endogenous bioreactors for systemic gene therapeutics. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[33] R. Herzog,et al. Major role of local immune responses in antibody formation to factor IX in AAV gene transfer , 2005, Gene Therapy.
[34] B. Byrne,et al. Gene delivery to skeletal muscle results in sustained expression and systemic delivery of a therapeutic protein. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[35] Yi Zhang,et al. Erythropoietin gene therapy leads to autoimmune anemia in macaques. , 2004, Blood.
[36] T. Flotte. Adeno-Associated Virus-Based Gene Therapy for Inherited Disorders , 2005, Pediatric Research.
[37] W. Hauswirth,et al. Production and purification of serotype 1, 2, and 5 recombinant adeno-associated viral vectors. , 2002, Methods.
[38] R. Herzog,et al. Influence of vector dose on factor IX-specific T and B cell responses in muscle-directed gene therapy. , 2002, Human gene therapy.
[39] T. Conlon,et al. Efficient hepatic delivery and expression from a recombinant adeno-associated virus 8 pseudotyped alpha1-antitrypsin vector. , 2005, Molecular therapy : the journal of the American Society of Gene Therapy.
[40] T. Flotte,et al. Sustained secretion of human alpha-1-antitrypsin from murine muscle transduced with adeno-associated virus vectors. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[41] R. Crystal,et al. Replacement therapy of alpha 1-antitrypsin deficiency. Reversal of protease-antiprotease imbalance within the alveolar structures of PiZ subjects. , 1981, The Journal of clinical investigation.
[42] T. Flotte,et al. Latent Adeno-Associated Virus Infection Elicits Humoral but Not Cell-Mediated Immune Responses in a Nonhuman Primate Model , 1999, Journal of Virology.
[43] R. Samulski,et al. Efficient long-term gene transfer into muscle tissue of immunocompetent mice by adeno-associated virus vector , 1996, Journal of virology.
[44] T. Flotte,et al. Production of clinical-grade recombinant adeno-associated virus vectors. , 2002, Current opinion in biotechnology.
[45] A. Heguy,et al. Intrapleural administration of a serotype 5 adeno-associated virus coding for α1-antitrypsin mediates persistent, high lung and serum levels of α1-antitrypsin , 2004 .
[46] R. Crystal,et al. Comparison of alpha-1-antitrypsin levels and antineutrophil elastase capacity of blood and lung in a patient with the alpha-1-antitrypsin phenotype null-null before and during alpha-1-antitrypsin augmentation therapy. , 2015, The American review of respiratory disease.